STAT

MARCH 5, 2023

This is the first article in a series about new obesity drugs that are transforming patients’ lives, dividing medical experts, and spurring one of the biggest business battles in years. Read more about The Obesity Revolution. A two-part message is permeating the halls of medicine and the fabric of society, sliding into medical school lectures, pediatricians’ offices, happy hours and social feeds: Obesity is a chronic biological disease — and it’s treatable with a new

Medical Schools 98

Medical Schools 98

The FDA Law Blog

MARCH 5, 2023

By Sara W. Koblitz — FDA uses its Product Specific Guidance documents (“PSGs”) to provide recommendations as to the bioequivalence testing necessary for approval of a generic drug. As the Office of Generic Drugs (“OGD”) has stated, “ [t]he clarity and transparency provided by PSGs help streamline generic drug product development, promote timely approval of Abbreviated New Drug Application (ANDA) submissions and increased drug competition, improving patient access to high quality and affordable

FDA 59

FDA Packaging Documentation 59

Med Ed 101

MARCH 5, 2023

The 2023 GOLD Guidelines were released a little while ago and I don’t think there is anything earth-shattering in medication selection. The biggest thing associated with these guidelines compared to previous editions is the fact that it encourages a little more aggressive therapy earlier. The ABCD categories based on symptoms and exacerbation risk has been […] The post The 2023 GOLD Guidelines and What Still Puzzles Me… appeared first on Med Ed 101.

52

52